Quarterly Report · 10-Q

GRI Bio, Inc.

GRINASDAQEQUITYCurrent

Quarterly Report

Filed Aug 14, 2026Accepted Aug 14, 2026, 7:44 AM EDTCIK 1824293Accession 0001824293-26-000055

Company context

GRI Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory, fibrotic and autoimmune diseases. The Company's lead program, GRI-0621, is an oral RARβ/γ-selective agonist being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening fibrotic lung disease with significant unmet need. GRI-0621 is designed to modulate pathways associated with inflammation, fibrosis and tissue repair and is being evaluated as a potential novel oral therapeutic for patients with IPF.

Current securities

GRINASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

GRI BIO, INC. · 10-Q · Filed 2026-08-14

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001per share

Symbol: GRI
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: c-1

Dimensions: Not supplied

Accession 000182429326000055 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.